EFPIA Disclosure Code
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Servier works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs) to learn from their knowledge and experience of patient's condition that is able to provide a true picture of what it is like to live with a specific condition, how care is delivered, how that impacts on them, their careers and families and how medicines and other treatments can change their quality of life and meet their needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Servier hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Servier certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Servier certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs, HCOs and POs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Servier certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO/PO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO/PO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Servier certifies that its disclosure complies with the Data Privacy obligations.

Date: July 22, 2021

Name of signatory: Olivier LAUREAU

Position in the Company: CEO

Signature:

EFPIA Disclosure Code
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Vifor Pharma Group works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Vifor Pharma Group hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Vifor Pharma Group certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Vifor Pharma Group certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Vifor Pharma Group certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Vifor Pharma Group certifies that its disclosure complies with the Data Privacy obligations.

Date: 31 May 2021

Name of signatory: Andreas Walde

Position in the Company: General Secretary

Signature: 

Inspired by patients.
Driven by science.

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom UCB works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, UCB hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

UCB certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

UCB certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

UCB certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

UCB certifies that its disclosure complies with the Data Privacy obligations.

Date: May 11, 2021

Name of signatory: Jean-Christophe Tellier

Position in the Company: Head of UCB, CEO

Signature:

EFPIA Code Disclosure
2021 Self-Certification Letter
Teva Pharmaceuticals Europe BV

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Teva Pharmaceutical Europe BV works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. In the same way, the pharmaceutical industry works with Patient Organizations (POs). This collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs, HCOs, and POs aims to build understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Teva Pharmaceutical Europe BV hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality
`

Teva Pharmaceutical Europe BV certifies that its disclosures of ToVs:

- have been completed in each EPFIA country where Teva Pharmaceutical Europe BV operates;
- include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA; and
- are further described in the respective country's Methodological Note.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Teva Pharmaceutical Europe BV certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Teva Pharmaceutical Europe BV certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate; and
- Decisions of local code authorities in response to the COVID19 pandemic.

Ensuring compliance with Data Privacy Obligations

Teva Pharmaceutical Europe BV certifies that its disclosure complies with the Data Privacy obligations.

Date:	June 30, 2021
Name of signatory:	Richard Daniell
Position in the Company:	Executive Vice President Teva Pharmaceuticals Europe BV
Signature:	DocuSigned by: F6D73ABE0D1B4C6...

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Takeda Pharmaceuticals International AG works, provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Takeda Pharmaceuticals International AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Takeda Pharmaceuticals International AG certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Takeda Pharmaceuticals International AG certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Takeda Pharmaceuticals International AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Takeda Pharmaceuticals International AG certifies that its disclosure complies with the Data Privacy obligations.

Date: 17.06.2021

Name of signatory: Giles Platford

Position in the Company: President Europe and Canada

Signature: 

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Shire, now part of Takeda Pharmaceuticals International AG works, provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Shire, now part of Takeda Pharmaceuticals International AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Shire, now part of Takeda Pharmaceuticals International AG certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Shire, now part of Takeda Pharmaceuticals International AG certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Shire, now part of Takeda Pharmaceuticals International AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Shire, now part of Takeda Pharmaceuticals International AG certifies that its disclosure complies with the Data Privacy obligations.

Date:	17.06.2021
Name of signatory:	Giles Platford
Position in the Company:	President Europe and Canada
Signature:	

SANOFI

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Sanofi works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Sanofi hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Sanofi certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

SANOFI

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Sanofi certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Sanofi certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Sanofi certifies that its disclosure complies with the Data Privacy obligations.

Date	June 15, 2021
Name of signatory	Olivier CHARMEIL
Position in the Company	EVP, General Medicines, SANOFI
Signature	

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom F. Hoffmann – La Roche (hereinafter "Roche") works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Roche hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Roche certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Roche certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Roche certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Roche certifies that its disclosure complies with the Data Privacy obligations.

Date: 22-May-2021

Name of signatory: Bill Anderson

Position in the Company: CEO

Signature: DocuSigned by: Bill Anderson 1F00FDC8BFE6487...

Date: 21-May-2021

Name of signatory: Padraic Ward

Position in the Company: Head of Roche Pharma International

Signature: DocuSigned by: Padraic Ward D0BBE571B2F14E9...

Pierre Fabre
Médicament

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom PIERRE FABRE MEDICAMENT works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, PIERRE FABRE MEDICAMENT hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

PIERRE FABRE MEDICAMENT certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

PIERRE FABRE MEDICAMENT certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

PIERRE FABRE MEDICAMENT certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

PIERRE FABRE MEDICAMENT certifies that its disclosure complies with the Data Privacy obligations.

Date: 27 MAI 2021

Jean-Luc LOWINSKI
Président

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Pfizer works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Pfizer hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Pfizer certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Pfizer certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Pfizer certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Pfizer certifies that its disclosure complies with the Data Privacy obligations.

Date:

Name of signatory: Angela Hwang

Position in the Company: Group President, Pfizer Biopharmaceuticals Group

Signature:

June 24, 2021

Otsuka Pharmaceutical Europe Ltd.
Gallions
Wexham Springs
Framewood Road
Wexham
SL3 6PJ
Phone: +44 (0)203 747 5000
Fax: +44 (0)1895 207115
Web: www.otsuka-europe.com
Registered in England No: 3456326

Otsuka-people creating new products for better health worldwide

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Otsuka Pharmaceutical Europe Ltd. works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Otsuka Pharmaceutical Europe Ltd. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Otsuka Pharmaceutical Europe Ltd. certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Otsuka Pharmaceutical Europe Ltd. certifies that:

Otsuka

Otsuka-people creating new products for better health worldwide

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Otsuka Pharmaceutical Europe Ltd. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Otsuka Pharmaceutical Europe Ltd. certifies that its disclosure complies with the Data Privacy obligations.

Date: 14th May 2021

Name of signatory: Andy Hodge

Position in the Company: President & CEO, Europe

Signature: 

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Novo Nordisk works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Novo Nordisk hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Novo Nordisk certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Novo Nordisk certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Novo Nordisk certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Novo Nordisk certifies that its disclosure complies with the Data Privacy obligations.

Date: 31-05-2021

Name of signatory: Lars Fruergaard Jørgensen

Position in the Company: President and Chief Executive Officer

Signature:

NOVARTIS | Reimagining Medicine

Novartis Pharma AG
Communication
Novartis Campus
Postfach
4002 Basel
Switzerland
T: +41 61 324 1321

EFPIA Disclosure Code - 2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Novartis Pharma AG works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle, pharma companies work with scientists and healthcare professionals. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, member companies made their best efforts to disclose relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Novartis Pharma AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2020 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Novartis Pharma AG certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Novartis Pharma AG certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs' and HCOs' transfers of value (each as defined in the EFPIA Disclosure Code).

NOVARTIS | Reimagining Medicine

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons.

Novartis Pharma AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

The collection, processing and disclosure of transfers of value have been made in accordance with the Data Privacy laws applicable in the respective countries.

Date: 11th June 2021

Name of signatory:
Susanne Schaffert

Position in the Company:
President Novartis Oncology

Signature

Frank K. Clyburn

EVP and President, Human Health
Merck & Co., Inc.

Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth, NJ 07033
U.S.A
Phone: 1.908-740-4000
merck.com

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Merck & Co., Inc. works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Merck & Co., Inc. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Merck & Co., Inc. certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Frank K. Clyburn

EVP and President, Human Health
Merck & Co., Inc.

Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth, NJ 07033
U.S.A
Phone: 1.908-740-4000
merck.com

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Merck & Co., Inc. certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Merck & Co., Inc. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Merck & Co., Inc. certifies that its disclosure complies with the Data Privacy obligations.

Date: May 11, 2021

Name of signatory: Frank K. Clyburn

Position in the Company: EVP and President, Human Health; Merck & Co., Inc.

Signature:



EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Merck works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Merck hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Merck certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Merck certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Merck certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Merck certifies that its disclosure complies with the Data Privacy obligations.

Date: May 26, 2021

Name of signatory: Belén Garijo

Position in the Company: Chair of the Executive Board and CEO of Merck

Signature:

A. MENARINI
INDUSTRIE FARMACEUTICHE RIUNITE

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom A. Menarini Industrie Farmaceutiche Riunite S.r.l. works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, A. Menarini Industrie Farmaceutiche Riunite S.r.l. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

A. MENARINI
INDUSTRIE FARMACEUTICHE RIUNITE

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that its disclosure complies with the Data Privacy obligations.

Date:

Name of signatory: Eric Cornut

Position in the Company: Chairman of the Board of Directors

Signature:

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom H. Lundbeck A/S ("Lundbeck") works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Lundbeck hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Lundbeck certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Lundbeck certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Lundbeck certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Lundbeck certifies that its disclosure complies with the Data Privacy obligations.

Date: May 31st 2021
Signature:

Deborah Dunsire
CEO, H. Lundbeck A/S

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A
+1 317 276 2000
www.lilly.com

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Eli Lilly and Company (Lilly) works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Lilly hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Lilly certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Lilly certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Lilly certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Lilly certifies that its disclosure complies with the Data Privacy obligations.

X

Alfonso G. Zulueta

Senior Vice President and President of Lilly International

May 2021

EFPIA Code Disclosure
2021 Self-Certification Scheme

Dermatology
beyond the skin

LEO Pharma A/S
Industriparken 55
2750 Ballerup
Denmark

Main +45 4494 5888
Fax +45 7226 3321

www.leo-pharma.com
CVR no.: 56 75 95 14

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom LEO Pharma works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, LEO Pharma hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

LEO Pharma certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

LEO Pharma certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

LEO Pharma certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

LEO Pharma certifies that its disclosure complies with the Data Privacy obligations.

Date: June 1, 2021

Name of signatory: **Catherine Mazzacco**

Position in the Company: **President & CEO**

Signature:

Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Janssen Pharmaceutica works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Janssen Pharmaceutica hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Janssen Pharmaceutica certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Janssen Pharmaceutica certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Janssen Pharmaceutica certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Janssen Pharmaceutica certifies that its disclosure complies with the Data Privacy obligations.

Date: May 5, 2021

Name of signatory: Kris Sterkens

Position in the Company: Company Group Chairman Janssen EMEA

Signature:

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Ipsen works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Ipsen hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Ipsen certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Ipsen certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Ipsen certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Ipsen certifies that its disclosure complies with the Data Privacy obligations.

Date: June 29, 2021

Name of signatory: David Loew

Position in the Company: Chief Executive Officer

Signature:



GlaxoSmithKline Services Unlimited
980 Great West Road
Brentford
Middlesex
TW8 9GS
T +44 2080 475 000
www.gsk.com

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom GlaxoSmithKline works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, GlaxoSmithKline hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

GlaxoSmithKline certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

GlaxoSmithKline certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Registered in England and Wales
No. 1047315
Registered Office
980 Great West Road, Brentford
Middlesex, TW8 9GS

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

GlaxoSmithKline certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

GlaxoSmithKline certifies that its disclosure complies with the Data Privacy obligations.

Date: 05 July 2021

Name of signatory: Luke Miels

Position in the Company: Chief Commercial Officer

Signature: 

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Gilead Sciences works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Gilead Sciences hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Gilead Sciences certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Gilead Sciences certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Gilead Sciences certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Gilead Sciences certifies that its disclosure complies with the Data Privacy obligations.

Date: 01 June 2021

Name of signatory: Rudolf Ertl

Position in the Company: Senior Vice President, ACE Commercial Operations

Signature:



EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with Eisai Europe Limited works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, (Eisai Europe Limited) hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Eisai Europe Limited certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Eisai Europe Limited certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Eisai Europe Limited certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Eisai Europe Limited certifies that its disclosure complies with the Data Privacy obligations.

Date: 02-Jul-2021 | 16:40:00 BST

Name of signatory: Nick Burgin

Position in the Company: President & COO EMEA & President General Value & Access

Signature: DocuSigned by: Nick Burgin DF29518349B8416...

Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

Daiichi Sankyo Europe GmbH · 81366 Munich · Germany

Daiichi Sankyo Europe GmbH
Zielstattstrasse 48
81379 Munich · Germany
Phone +49 89 78080
Fax +49 89 7808267
service@daiichi-sankyo.eu
www.daiichi-sankyo.eu

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Daiichi Sankyo Europe GmbH works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Daiichi Sankyo Europe GmbH hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Daiichi Sankyo Europe GmbH certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Daiichi Sankyo Europe GmbH certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Daiichi Sankyo Europe GmbH certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Daiichi Sankyo Europe GmbH certifies that its disclosure complies with the Data Privacy obligations.

Date : 10 June 2021

Name of signatory: Curd Lejaegere

Position in the Company: DSE representative to EFPIA
VP EU Mid-Sized Countries

Signature: 

CHIESI FARMACEUTICI S.p.A.
26/A, Via Palermo
43122 Parma - Italy
Phone +39 0521 2791
Fax: +39 0521 774468

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Chiesi Farmaceutici S.p.A. works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Chiesi Farmaceutici S.p.A. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Chiesi Farmaceutici S.p.A. certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Chiesi Farmaceutici S.p.A. certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

CHIESI FARMACEUTICI S.p.A.
26/A, Via Palermo
43122 Parma - Italy
Phone +39 0521 2791
Fax: +39 0521 774468

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Chiesi Farmaceutici S.p.A. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Chiesi Farmaceutici S.p.A. certifies that its disclosure complies with the Data Privacy obligations.

Date:	June 16th, 2021
Name of signatory:	Alberto Chiesi
Position in the Company:	President
Signature:	

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Celgene works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Celgene hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Celgene certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Celgene certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Celgene certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Celgene certifies that its disclosure complies with the Data Privacy obligations.

Date:

Name of signatory: Christopher Boerner

Position in the Company: EVP, Chief Commercialization Officer

Signature: Christopher Boerner

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Bristol-Myers Squibb works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Bristol-Myers Squibb hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Bristol-Myers Squibb certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Bristol-Myers Squibb certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Bristol-Myers Squibb certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Bristol-Myers Squibb certifies that its disclosure complies with the Data Privacy obligations.

Date:

Name of signatory: Christopher Boerner

Position in the Company: EVP, Chief Commercialization Officer

Signature: Christopher Boerner

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom **Biogen International GmbH (Biogen)** works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, **Biogen** hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Biogen certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Biogen certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Biogen certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Biogen certifies that its disclosure complies with the Data Privacy obligations.

Date: 15th June 2021

Name of signatory: Johanna Friedl-Naderer

Position in the Company: President Europe, Canada & Partner Markets

Signature: DocuSigned by: Johanna Friedl-Naderer E770471D5B234DF...

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Amgen works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Amgen hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Amgen certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Amgen certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Amgen certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Amgen certifies that its disclosure complies with the Data Privacy obligations.

Date: 5/18/2021

Name of signatory: Murdo Gordon

Position in the Company: Executive Vice President Global Commercial Operations

Signature:

DocuSigned by:

Signer Name: Murdo Gordon
Signing Reason: I approve this document
Signing Time: 5/18/2021 | 11:30:22 AM PDT

461AC89E462847C9A2D3F0A5002098E9

astellas

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Astellas Pharma Europe Ltd works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Astellas Pharma Europe Ltd hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Astellas Pharma Europe Ltd certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Astellas Pharma Europe Ltd certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

astellas

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Astellas Pharma Europe Ltd certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Astellas Pharma Europe Ltd certifies that its disclosure complies with the Data Privacy obligations.

Date: 10.06.2021

Name of signatory: Mr. Dirk Kosche

Position in the Company: President of Established Markets- Commercial

Signature:

Astellas Pharma Europe Limited.
300 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey, KT15 2NX

abbvie

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom AbbVie works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, AbbVie hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

AbbVie certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

AbbVie certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

AbbVie Europe
10 rue d'Arcueil
94150 Rungis
France
Tél. : +33 (0)1 45 60 15 50

Succursale Française AbbVie Biopharmaceuticals GmbH
RC de Zoug . CH-170.4.011.236-4
Siège social : Neuhofstrasse 23, 6341 Baar
RCS Créteil 752 319 343

abbvie

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

AbbVie certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

AbbVie certifies that its disclosure complies with the Data Privacy obligations.

Date: 14 June 2021

Name of signatory: Esteban PLATA

Position in the Company: SVP, President International, WE&C

Signature:



AbbVie Europe
10 rue d'Arcueil
94150 Rungis
France
Tél. : +33 (0)1 45 60 15 50

Succursale Française AbbVie Biopharmaceuticals GmbH
RC de Zoug . CH-170.4.011.236-4
Siège social : Neuhofstrasse 23, 6341 Baar
RCS Créteil 752 319 343

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Bial-Portela & Cª, SA works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Bial-Portela & Cª, SA hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Bial-Portela & Cª, SA certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

À AV. DA SIDERURGIA NACIONAL • 4745-457 CORONADO (S. Romão e S. Mamede) • PORTUGAL • Tel.: +351 22 986 6100 • Fax: +351 22 986 6190 • www.bial.com • info@bial.com
Sociedade Anónima • Cons. Reg. Com. Trofa Matrícula nº 500 220 913 • NIPC 500 220 913 • Capital Social €50.000.000

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Bial-Portela & Cª, SA certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Bial-Portela & Cª, SA certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Bial-Portela & Cª, SA certifies that its disclosure complies with the Data Privacy obligations.

Date: 2021.05.04

Name of signatory: António Portela

Position in the Company: Chief Executive Officer

Signature: 

À AV. DA SIDERURGIA NACIONAL • 4745-457 CORONADO (S. Romão e S. Mamede) • PORTUGAL • Tel.: +351 22 986 6100 • Fax: +351 22 986 6190 • www.bial.com • info@bial.com
Sociedade Anónima • Cons. Reg. Com. Trofa Matrícula nº 500 220 913 • NIPC 500 220 913 • Capital Social €50.000.000

AstraZeneca AG
Neuhofstrasse 34
6340 Baar, Switzerland
T: +41 (0) 41 725 75 75
F: +41 (0) 41 725 76 76
astrazeneca.com

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom AstraZeneca works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, AstraZeneca hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

AstraZeneca certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

AstraZeneca certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

AstraZeneca certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

AstraZeneca certifies that its disclosure complies with the Data Privacy obligations.

Date: 21.06.2021

Name of signatory: Iskra Reic

Position in the Company: Executive Vice President Europe & Canada

Signature: 

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Bayer AG works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Bayer AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Bayer AG certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Bayer AG certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Bayer AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Bayer AG certifies that its disclosure complies with the Data Privacy obligations.

Bayer Aktiengesellschaft

Berlin, 14.6.21

Stefan Oelrich
Member of the Board of Management
President Pharmaceuticals Division

Berlin, June 14, 2021

ppa. Königer

Dr. Ursula Königer
Law, Patents and Compliance
Business Partner Pharmaceuticals

Boehringer Ingelheim

C. H. Boehringer Sohn AG & Co. KG · 55216 Ingelheim am Rhein

C. H. Boehringer Sohn AG & Co. KG

EFPIA
Leopold Plaza Building
Rue du Trone
1050 Bruxelles
BELGIUM

14. Juni 2021

Ihr Zeichen

Unser Zeichen

Dokument4

Telefon
Telefax
E-Mail

Binger Straße 173
55216 Ingelheim am Rhein
Telefon 06132 77-0
Telefax 06132 72-0
www.boehringer-ingelheim.com

Kommanditgesellschaft

Sitz Ingelheim am Rhein
Registergericht Mainz
HR A 21732

Deutsche Bank AG
BIC: DEUTDE5MXXX
IBAN:
DE26 5507 0040 0010 4232 00

Komplementär
Boehringer AG

Vorstand
(Unternehmensleitung)
Hubertus von Baumbach
(Vorsitzender)
Carinne Knoche-Brouillon
Dr. Michel Pairet
Jean Scheftsik de Szolnok
Michael Schmelmer

Vorsitzender des Aufsichtsrates
Christian Boehringer

Sitz Ingelheim am Rhein
Registergericht Mainz
HR B 23354

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Boehringer Ingelheim works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.
In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Boehringer Ingelheim hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Boehringer Ingelheim

Disclosure quality

Boehringer Ingelheim certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Boehringer Ingelheim certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Boehringer Ingelheim

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Boehringer Ingelheim certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Boehringer Ingelheim certifies that its disclosure complies with the Data Privacy obligations.

Date: June 15, 2021

Name of signatory: Hubertus von Baumbach

Position in the Company: Chairman of the Board of Managing Directors

Signature:

EFPIA Code Disclosure
2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Almirall S.A. works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Almirall S.A. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Almirall S.A. certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Almirall S.A. certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Almirall, S.A.
Rda. General Mitre, 151
08022 Barcelona, Spain
P +34 93 291 30 00
F +34 93 291 31 80
almirall.com

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Almirall S.A. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Almirall S.A. certifies that its disclosure complies with the Data Privacy obligations.

Date: 06-18-2021

Name of signatory: Gianfranco Nazzi

Position in the Company: CEO

Signature: 

Almirall, S.A.
Rda. General Mitre, 151
08022 Barcelona, Spain

P +34 93 291 30 00
F +34 93 291 31 80

almirall.com